Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
BSEGUJARAT TERCE LABORATORIES LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 28 Jul, 2026 · 20:24 IST

Gujarat Terce Labs FY26 Annual Report: Revenue down 5%, PAT turns around

Revenue DeclineEbitda Margin CompressionPat Growth 25pctResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+11.0%Reaction day
₹33.41
prior close
₹34.30
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.5%+10.6% vs market
Pharmaceuticals peers, median of 160sector+0.8%+10.3% vs sector

On the reaction day the stock moved 10.6 pts more than Nifty Microcap 250 and 10.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+2.0
10m
+2.0
15m
+2.0
30m
+2.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+11.0+0.5+10.6+0.8+10.3
Next day
+8.5-0.1+8.6-0.0+8.5
2d
+13.7+1.0+12.8+0.1+13.7
3d
+23.9+2.3+21.6+0.6+23.3
4d
+25.7+2.8+22.9+1.0+24.7
5d
+25.6+4.1+21.5+0.6+25.0
1w
+28.7+4.5+24.2+1.5+27.2
15d
+7.8+4.8+3.0+0.3+7.4
1m
+15.4+6.4+9.0+1.9+13.5
2m
+8.5+5.5+3.0+3.3+5.2
3m
+28.6-1.7+30.3-2.2+30.8
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

FY26 revenue at D47.47 crore, down 5.4% YoY due to reduced B2B operations and Acolate Plus regulatory hit. EBITDA at D3.63 crore with margin of 7.66% versus 8.35% last year. PAT swung to D2.20 crore profit from D97.87 lakh loss. Net worth grew over 50%, long-term debt near zero, and operating cash flow stayed positive for a second straight year.

Likely market impact

Topline dipped but profitability turned around sharply. Balance sheet strengthened with near-zero debt, and promoter holding rose to 40%.